# nature portfolio

Corresponding author(s):	Kelsey E. Johnson
Last updated by author(s):	May 20, 2024

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

		CS

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	$\blacksquare$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	🗶 A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
x	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
x	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated
'	Our web collection on statistics for high airts contains articles on many of the points above

### Software and code

Policy information about <u>availability of computer code</u>

Data collection

N/A

Data analysis

No custom algorithms or software were used. Analyses used: RNA-SeQC v2.3.4, Bowtie2 v 2.2.4, DESeq2 v1.30.0, R version 4.3.1, enrichR v3.2, ggplot2 v3.4.2, ggbeeswarm v0.7.2, tidyr v1.3.0, dplyr v1.1.2, vegan v2.6-4, Shi7 v1.0.1, BURST v0.99.7, HUMAnN 3.0.0, lavaan v0.6-17. Code to reproduce figures is available at https://github.com/kelsj/CMV\_milk\_genomics.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

#### Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Milk metabolite abundances, gene expression matrices, and microbial abundance tables are available as extended data tables (see descriptions in supplementary material). Milk RNA sequencing data is available at dbGaP study accession phs003408.v1.p1, and metagenomic sequencing data SRA accession PRJNA1019702.

## Research involving human participants, their data, or biological material

Policy information a and sexual orientati		vith human participants or human data. See also policy information about sex, gender (identity/presentation), thnicity and racism.			
Reporting on sex and	d gender	All adult participants were female as this study included lactating individuals recruited prenatally while gestating their infants, and thus were of female sex. We did not have information on gender identity. Infant growth Z-scores were sex-specific and so infant sex was not included as an additional covariate.			
		We used self-reported race as a covariate in our study, as there are previously reported discrepancies in the rate of CMV by race/ethnicity in the United States.			
Population characte	ristics	Infant and maternal age, household income, education levels, parity, and self-identified race were included in our study.			
Recruitment		Participants were recruited through their Ob/Gyn clinic during routine prenatal care.			
th		All participants provided written informed consent and the study protocols were approved by institutional review boards at the University of Minnesota, HealthPartners Institute for Education and Research, and the University of Oklahoma Health Sciences Center.			
Note that full informat	tion on the appr	oval of the study protocol must also be provided in the manuscript.			
	. 6:				
<u>Field-spe</u>	<u>citic re</u>	porting			
Please select the on	e below that is	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
<b>X</b> Life sciences	□ в	ehavioural & social sciences			
For a reference copy of th	ne document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
Life scien	ces stu	udy design			
All studies must disc	close on these	points even when the disclosure is negative.			
Sample size	Samples and da	ata were collected prior to this study, so no prospective sample size calculations were done.			
Data exclusions	Subjects/sampl	es were excluded if they had missing data for each analysis.			
Replication	N/A				
Randomization	N/A				
Blinding	N/A				
Reporting	g for sr	pecific materials, systems and methods			
We require informatio	n from authors	about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.			
Materials & exp	erimental s	ystems Methods			
n/a Involved in the	e study	n/a Involved in the study			
Antibodies  Eukaryotic of	_ _				
Clinical data					
	search of concer	n			
<b>∡</b>					